Alfred Chung, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #6304
San Francisco CA 94117
ORCID ORCID Icon0000-0003-0196-5456 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Michigan - Ann ArborBSE05/2010Chemical Engineering
    Northwestern University - Feinberg School of MedicineMD05/2014Medicine
    Stanford University06/2017Residency, Internal Medicine
    Stanford University06/2020Fellowship, Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system.

    Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma.

    After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology.

    Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma. Blood Adv. 2024 Mar 01. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A. PMID: 38429087.
      View in: PubMed   Mentions:    Fields:    
    2. Monoclonal Gammopathy of Anemic Significance? Resolution of Pure Red Cell Aplasia With Daratumumab-Based Therapy. Am J Med. 2024 Feb 22. Khan O, Prakash S, Chung A, Wong SW, Kennedy VE. PMID: 38401677.
      View in: PubMed   Mentions:    Fields:    
    3. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1888-1891. Duvalyan E, Shah N, Lo M, Martin T, Wolf JL, Chung A, Arora S, Huang CY, Wong SW. PMID: 37599633.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2023 08; 29(8):504.e1-504.e7. Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Martin TG, Shah N, Banerjee R. PMID: 37244643.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk Lymphoma. 2023 06; 64(6):1186-1193. Natsuhara KH, Huang CY, Knoche J, Arora S, Chung A, Martin T, Wolf J, Wong SW, Shah N, Banerjee R. PMID: 37096638.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplant Cell Ther. 2023 06; 29(6):350-355. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R. PMID: 36933659.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. Br J Haematol. 2023 06; 201(5):935-939. Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N. PMID: 36846905.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Curr Probl Cancer. 2023 06; 47(3):100953. Kennedy VE, Natsuhara K, Maringanti SA, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW. PMID: 36807996.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. J Oncol Pharm Pract. 2023 Oct; 29(7):1715-1724. Rath C, Yoo C, Cheplowitz H, Lo M, Young R, Guglielmo J, Saunders IM, Banerjee R, Young R, Kumar A, Chung A, Rosenberg AS, Costello C, Fine J, Wilson M, Patel N, Banez MT. PMID: 36731514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022 11; 199(4):520-528. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. PMID: 36041779; PMCID: PMC9538250.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    11. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Adv. 2020 02 11; 4(3):458-466. Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. PMID: 32027745; PMCID: PMC7013253.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    12. Cutaneous plasmablastic plasmacytoma. Blood. 2019 12 05; 134(23):2116. Chung A, Liedtke M. PMID: 31805196.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Pract Res Clin Haematol. 2019 03; 32(1):54-64. Chung A, Liedtke M. PMID: 30927976.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. J Cardiothorac Surg. 2018 Feb 07; 13(1):20. Beel AJ, Demos DS, Chung A, Liao C, Lui NS. PMID: 29415746; PMCID: PMC5804049.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet. 2017 Oct; 216-217:10-15. Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD. PMID: 29025582.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Differential solute gas response in ionic-liquid-based QCM arrays: elucidating design factors responsible for discriminative explosive gas sensing. Anal Chem. 2011 Oct 15; 83(20):7823-33. Rehman A, Hamilton A, Chung A, Baker GA, Wang Z, Zeng X. PMID: 21863884.
      View in: PubMed   Mentions: 7     Fields:    
    17. An accurate model of polyglutamine. Proteins. 2011 May; 79(5):1427-40. Digambaranath JL, Campbell TV, Chung A, McPhail MJ, Stevenson KE, Zohdy MA, Finke JM. PMID: 21337625.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    18. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010 Sep; 78(3):524-33. Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR. PMID: 20571077; PMCID: PMC2939488.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    Alfred's Networks
    Concepts (69)
    Derived automatically from this person's publications.
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _